Company intelligence / Profile preview
TNA Therapeutics
New York, New York, United Statestnatherapeutics.com ↗
- Ownership
- Private
- Employees
- ~9
- Development stage
- Other
01
Overview
TNA Therapeutics is developing TNAT-101, an oral small molecule inhibitor of BCL3. The compound has shown preclinical efficacy in targeting cancer stem cells, reducing metastasis, and synergizing with immune checkpoint inhibitors. IND-enabling studies are ongoing to support the initiation of clinical trials in solid and hematological malignancies, including colorectal and metastatic breast cancers.
- Therapeutic areas
- OncologyHematology
- Modalities
- Small molecule
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Innovate UK
Beyond the preview
Go deeper on TNA Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TNA Therapeutics.